Michelle R. Garnsey

Michelle R. Garnsey

Auto-generated profile, based on publicly available information

Michelle R. Garnsey

Department of Chemistry, Duke University, Durham, North Carolina 27708

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2019 in Organic Letters
Verified
Journal Article
Closed access
JLJennie Liao
Jennie Liao
CBCorey H. Basch
Corey H. Basch
MHMegan E. Hoerrner
Megan E. Hoerrner
MTMichael R. Talley
Michael R. Talley
BBBrian P. Boscoe
Brian P. Boscoe
MWMary P. Watson
Mary P. Watson

10 May 2018 in Organic Letters
Verified
Journal Article
Closed access
JLJennie Liao
Jennie Liao
WGWeiye Guan
Weiye Guan
BBBrian P. Boscoe
Brian P. Boscoe
JTJoseph W. Tucker
Joseph W. Tucker
JTJohn W. Tomlin
John W. Tomlin
MWMary P. Watson
Mary P. Watson

30 August 2024 in Science Advances
Verified
Journal Article
Open access
MGMichelle R. Garnsey
Michelle R. Garnsey
MRMatthew C. Robinson
Matthew C. Robinson
LNLuong T. Nguyen
Luong T. Nguyen
RCRhonda Cardin
Rhonda Cardin
JTJoseph Tillotson
Joseph Tillotson
ALAlpha A. Lee
Alpha A. Lee
Vaccines and first-generation antiviral therapeutics have provided important protection against COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there remains a need for additional therapeutic options that provide enhanced efficacy and protection against potential viral resistance. The SARS-CoV-2 papain-like protease (PL pro ) is one of the two essential cysteine proteases involved in viral replication. While inhibitors of the SARS-CoV-2 main protease have demonstrated clinical efficacy, known PL pro inhibitors have, to date, lacked the inhibitory potency and requisite pharmacokinetics to demonstrate that targeting PL pro translates to in vivo efficacy in a preclinical setting. Here, we report the machine learning–driven discovery of potent, selective, and orally available SARS-CoV-2 PL pro inhibitors, with lead compound PF-07957472 ( 4 ) providing robust efficacy in a mouse-adapted model of COVID-19 infection.

7 July 2010 in Organic Letters
Verified
Journal Article
Closed access
MKMark C. Kohler
Mark C. Kohler
JYJulianne M. Yost
Julianne M. Yost
MGMichelle R. Garnsey
Michelle R. Garnsey
DCDon M. Coltart
Don M. Coltart

1 April 2011 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MGMichelle R. Garnsey
Michelle R. Garnsey
JMJames A. Matous
James A. Matous
JKJesse J. Kwiek
Jesse J. Kwiek
DCDon M. Coltart
Don M. Coltart

19 February 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MGMichelle R. Garnsey
Michelle R. Garnsey
ASAaron C. Smith
Aaron C. Smith
JPJana Polivkova
Jana Polivkova
AAAutumn L. Arons
Autumn L. Arons
GBGuoyun Bai
Guoyun Bai
MSMatthew F. Sammons
Matthew F. Sammons